Clearlyderm, Llc

CLIA Laboratory Citation Details

2
Total Citations
6
Total Deficiencyies
5
Unique D-Tags
CMS Certification Number 10D2078624
Address 22191 Powerline Rd Suite 29c, Boca Raton, FL, 33433
City Boca Raton
State FL
Zip Code33433
Phone(561) 353-3376

Citation History (2 surveys)

Survey - August 19, 2025

Survey Type: Standard

Survey Event ID: 5NC811

Deficiency Tags: D0000 D5209 D3011 D5609

Summary:

Summary Statement of Deficiencies D0000 An announced CLIA recertification survey was conducted at Schweiger Dermatology Group PA on August 19, 2025. The laboratory was not in compliance with 42 CFR Part 493, Requirements for Laboratories. The following is a description of the standard level deficiencies: D3011 FACILITIES CFR(s): 493.1101(d) Safety procedures must be established, accessible, and observed to ensure protection from physical, chemical, biochemical, and electrical hazards, and biohazardous materials. This STANDARD is not met as evidenced by: Based on observation, review of reagent safety data sheets and staff interview, the laboratory failed to ensure protection from chemical hazards from 08/25/2023 through 08/21/2025. Findings included: 1. During a tour of the laboratory on 8/19/2025 at 1:15 PM, there was no fume hood noted over the staining work station. The Stat Lab 100% Reagent Alcohol, and Stat Lab XS-3 Xylene Substitute were observed stored in the safety cabinet with respiratory hazard symbol on the labels. 2. Review of the Addendum to Mohs Overview: Staining Protocol listed the 100% Reagent Alcohol and XS-3 Xylene Substitute as being used for staining of Mohs Slides. 3. Review of the Safety Data Sheets (SDS) for 100% Reagent Alcohol noted it can cause respiratory irritations, drowsiness or dizziness. 4. Review of the SDS for XS-3 Xylene Substitute noted, "High concentrations may cause central nervous system depression such as dizziness, vomiting, numbness, drowsiness, headache, and similar narcotic symptoms." 5. During an interview on 08/19/2025 at 2:43 PM, the Mohs Pathology Supervisor confirmed the laboratory had no fume hood. D5209 PERSONNEL COMPETENCY ASSESSMENT POLICIES CFR(s): 493.1235 Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- As specified in the personnel requirements in subpart M, the laboratory must establish and follow written policies and procedures to assess employee and, if applicable, consultant competency. This STANDARD is not met as evidenced by: Based on record review of personnel records and interview, the laboratory failed to perform competency assessment on one of one Testing Personnel in 2024, (A). Findings: 1. Review of the Laboratory Personnel Report, signed by the Laboratory Director on 08/15/2025, listed one Testing Personnel (A) who performed interpretation of the H & E stained slides. 2. Review of the personnel records revealed there was no competency assessment for Testing Personnel A for 2024. 3. During an interview on 08/19/2025 at 2:50 PM, the Mohs Pathology Supervisor acknowledged there was no documentation of competency assessments performed on Testing Personnel A in 2024. D5609 HISTOPATHOLOGY CFR(s): 493.1273(e)(f) (e) The laboratory must use acceptable terminology of a recognized system of disease nomenclature in reporting results. (f) The laboratory must document all control procedures performed, as specified in this section. This STANDARD is not met as evidenced by: Based on record review and interview, the laboratory failed to list the dates the reagents used for Hematoxylin and Eosin (H&E) stain were opened from 04/14/2023 to 08/19/2025. Findings: 1. Review of the Reagent Logs for 2023, 2024, and 2025 showed there was no open dated listed for the reagents used in the H&E stain. 2. During an interview on 08/19/2025 at 2:43 AM, the Mohs Pathology Supervisor acknowledged the laboratory did not list the open dates for the reagents on the Reagent Log. -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - April 14, 2023

Survey Type: Standard

Survey Event ID: NOIU11

Deficiency Tags: D0000 D5473

Summary:

Summary Statement of Deficiencies D0000 A recertification survey conducted on 04/14/2023 found the CLEARLYDERM, LLC clinical laboratory not in compliance with 42 CFR Part 493, Requirements for Laboratories. D5473 CONTROL PROCEDURES CFR(s): 493.1256(e)(2)(g) (e) For reagent, media, and supply checks, the laboratory must do the following: (e) (2) Each day of use (unless otherwise specified in this subpart), test staining materials for intended reactivity to ensure predictable staining characteristics. Control materials for both positive and negative reactivity must be included, as appropriate. (g) The laboratory must document all control procedures performed. This STANDARD is not met as evidenced by: Based on record review and interview, the laboratory failed to have documentation of the acceptability of the Quality Control (QC) slide for Hematoxylin & Eosin (H&E) stain for 17 out of 62 testing dates from 01/05/2022 to 04/12/2023. Findings included: The laboratory uses the "Clearly Derm LLC Boca Control Slide Daily Log" to record the acceptability of the H&E stain. Review of the QC form showed that under the column "Results" it was missing the signature of the Mohs surgeon documenting the review and acceptability of the QC slide for the following dates: 06/29/2022, 12/07 /2023, 12/14/2022, 12/21/2022, 12/28/2022, 01/04/2023, 01/18/2023, 01/25/2023, 02 /01/2023, 02/08/2023, 02/15/2023, 02/22/2023, 03/01/2023, 03/08/2023, 03/15/2023, 03/22/2023, 03/29/2023, 04/05/2023, 04/12/2023. During an interview on 04/14/2023 at 11:30 AM the Office Consultant confirmed that the laboratory failed to document the acceptability of the Daily QC slide for H& E Stain for the days listed above. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 1 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access